Han, MeiLan K.
Ray, Riju
Foo, Jason
Morel, Chaienna
Hahn, Beth
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 7 February 2018
Revised: 25 July 2018
Accepted: 25 July 2018
First Online: 27 August 2018
Competing interests
: The authors met the criteria for authorship as recommended by the International Committee of Medical Journal Editors. R.R. and B.H. are employees of GSK and hold stocks/shares in GSK, but received no direct compensation related to the development of this manuscript. M.K.H. is an employee of University of Michigan, and reports consulting fees from Boehringer Ingelheim, GSK and AstraZeneca. She also reports research support from Novartis and Sunovion. J.F. and C.M. are employees of MAPI, a healthcare consulting company contracted by GSK for the conduct of this study. Anoro is owned by or licensed to the GSK group of companies. Respimat, Handihaler, and Stiolto are registered trademarks of Boehringer Ingelheim. Bevespi is a registered trademark of the AstraZeneca group of companies and Utibron is a trademark of Novartis AG, used under license. GSK also supported publication of this article.